This dosage information may not include all the information needed to use Dolasetron safely and effectively. See additional information for Dolasetron.
The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Nausea/Vomiting - Chemotherapy Induced
100 mg orally may be given for prevention within one hour before chemotherapy.
Usual Adult Dose for Nausea/Vomiting - Postoperative
12.5 mg IV given for prevention 15 minutes before the cessation of anesthesia or for treatment as soon as nausea or vomiting presents.
Alternatively, 100 mg orally may be given for prevention within two hours before surgery.
Usual Pediatric Dose for Nausea/Vomiting - Postoperative
>=2 years: 0.35 mg/kg (max: 12.5 mg) IV given for prevention 15 minutes before the cessation of anesthesia or for treatment as soon as nausea or vomiting presents.
Alternatively, 1.2 mg/kg (max: 100 mg) orally may be given for prevention within two hours before surgery.
Usual Pediatric Dose for Nausea/Vomiting - Chemotherapy Induced
>= 2 years: 1.8 mg/kg (max: 100 mg) orally may be given for prevention within one hour before chemotherapy.
Renal Dose Adjustments
No adjustment recommended
Liver Dose Adjustments
No adjustment recommended
Dolasetron may cause ECG interval changes (PR, QTc, ST prolongation and QRS widening). These changes are related in magnitude and frequency to blood levels of the active metabolite, and are self-limiting with declining blood levels. Some patients have interval prolongations for 24 hours or longer. Interval prolongation may lead to cardiovascular consequences, including heart block or cardiac arrhythmias.
Dolasetron should be administered with caution in patients who have or may develop prolongation of cardiac conduction intervals, particularly QTc. These include patients with hypokalemia or hypomagnesemia, patients taking diuretics with potential for inducing electrolyte abnormalities, patients with congenital QT syndrome, patients taking antiarrhythmic drugs or other drugs which lead to QT prolongation, and cumulative high dose anthracycline therapy.
Cross hypersensitivity reactions have been reported in patients who received other selective 5-HT3 receptor antagonists. Such reactions have not been seen with dolasetron mesylate.
Dolasetron should be administered with caution in pediatric patients who have or may develop prolongation of cardiac conduction intervals, particularly QTc. Rare cases of sustained supraventricular and ventricular arrhythmias, cardiac arrest leading to death, and myocardial infarction have been observed in children and adolescents.
No overall differences in safety and effectiveness were reported between geriatric and younger patients, and other reported clinical experience has not identified differences in responses between elderly and younger patients, but greater sensitivity of some elderly individuals cannot be ruled out.
Data not available
Dolasetron injection may be used for oral administration in children. Mix dose in apple or apple-grape juice. The diluted product may be kept at room temperature and used within 2 hours of preparation.